Estimating the social and economic benefits of pharmaceutical innovation: modeling clinical trial results in hiv disease

Research in Human Capital and Development

Volumn 14, Issue , 2001, Pages 175-196

  Simpson, Kit ^a   Voit, Eberhard ^a   Goodman, Russell ^a   Chumney, Elinor ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0038187426     PISSN: 01943960     EISSN: None     Source Type: Book Series    
DOI: 10.1016/s0194-3960(01)14008-4     Document Type: Article

References (43)

1. A. Alioum V. Leroy D. Commenges Effect of gender, age, transmission category, and antiretroviral therapy on the progression of HIV infection using multistate Markov models Epidemiology 9 6 1998 605 612
2. F.L. Altice G.H. Friedman The era of adherence to HIV therapy Annals of Internal Medicine 129 1998 503 505
3. AVANTI Analysis of HIV-clinical trials: statistical magic? Lancet 353 9169 1999 2061 2064
4. H.X. Barnhart M.B. Caldwell P. Thomas Natural history of human immunodeficiency virus disease in perinatally infected children: an analysis from the Pediatric Spectrum of Disease Project Pediatrics 97 5 1996 710 716
5. J. Bartlett The John Hopkins Hospital 2000–2001 guide to medical care of patients with HIV infection 9th ed. 2000 Lippincott Williams & Wilkins Philadelphia
6. A.M. Bayoumi D.A. Redelmeier Cost-utility analysis of rifubutin for Mycobacterium avium complex prophylaxis in patients with human immunodeficiency virus Conf. Retroviruses Opportunistic Infect 1996
7. A.K. Biddle K.N. Simpson Modeling the cost effectiveness of nevirapine triple combination therapy and dual combination therapy for the treatment of HIV disease in the United Kindom J. Medical Economics 2 1999 85 105
8. S. Bozzette G. Joyce D. McCaffrey Expenditures for the care of HIV-infected patients in the era of highly active antiretrovial therapy N. Engl. J. Med. 344 2001 817 823
9. R. Brown K.N. Simpson A. Nabulsi Costs and consequences of adding ritonavir to current antiviral therapy for advanced HIV patients in the United Kingdom and in the USA Int. Conf. AIDS 11 1996 78 (2)
10. S.B. Cantor R.W. Carson S.J. Spann A cost-effectiveness analysis of epoetin usage for patients with AIDS Pharmacoeconomics 3 3 1993 244 249
11. J.V Chancellor A.M. Hill C.A Sabin K.N. Simpson M. Youle Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection Pharmacoeconomics 12 1997 54 66
12. J. Cook E. Dasback P. Coplan Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial Research and Human Retroviruses 15 6 1999 499 508
13. W. Cunningham L. Markson R. Andersen Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the United States Journal of Acquired Immune Deficiency Syndrome (JAIDS) 25 2000 115 123
14. Deficiency Syndromes 16 1 1997 15 21
15. P. Dolan Modeling valuations for EuroQoL health states Medical Care 35 1998 1095 1108
16. A. Downs S.H. Heisterkamp J.B. Brunet Reconstruction and prediction of the HIV/AIDS epidemic among adults in the European Union and in the low prevalence countries of central and eastern Europe AIDS 11 5 1997 649 662
17. K.A. Freedberg J.A. ScharLstein G.R. Seage 2 E. Losina M.C. Weinstein D.E. Craven A.D. Paltiel The cost-effectiveness of preventing AIDS-related opportunistic infections JAMA 279 1998 130 136 3rd
18. K. Freedberg E. Losina M. Weinstein The cost-effectiveness of combination antiretroviral therapy for HIV disease N. Engl. J. Med. 344 2001 824 831
19. J. Gathe A. Chu C. Kass W. Paxton Three year experience with nelfinavir combination therapy 13th International AIDS Conference July 9–14. Durban, SA 2000 Abstract TuPeB3236
20. A. Gigh A. Verdecchia Uncertainty of AIDS incubation time and its effects on back-calculation estimates Stat. Med. 19 2 2000 175 189
21. S.J. Goldie K.M. Kuntz M.C. Weinstein K.A. Freedberg M.L. Welton J.M. Palefsky The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men JAMA 281 19 1999 1822 1829
22. R. Gulick J.W. Mellors D. Havlir J.J. Eron 3-Year suppression of HIV viremia with indinavir, zidovudine and lamivudine Annals of Internal Medicine 133 2001 35 39
23. S. Hammer K. Squires M. Hughes A Controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less New England Journal of Medicine 337 11 1997 725 733
24. P.M. Hartigan L. Rabeneck T.J. Menke Using a Markov model to predict numbers of HIV+ patients presenting for care to the VA health care system Health Serv. Res. 14 1997 277 278
25. R. Hays D. Sackett J. Gray Transferring evidence from research into practice: Getting the evidence straight ACP Journal Club 1997 A-14-16
26. F. Hellinger J. Fleishman Estimating the national cost of treating people with HIV disease: patient, payer, and provider data Journal of Acquired Immune Deficiency Syndrome (JAIDS) 24 2000 182 188
27. I.M. Longini Jr. R.H. Byers C.R. Horsburgh Estimation of the stage-specific incidence and prevalence of HIV infection by using a Markov model and backcalculation Int. Conf. AIDS 6 1990 (2)
28. Marshall D. A., Simpson K. N., Norton E. C., Biddle A. K., Youle M., (forthcoming). Measuring the Effect of Clinical Guidelines on Patient Outcomes: HIV/AIDS Intl. J. Technology Assessment in Hlth. Care.
29. J.A. Mauskopf J.M. Tolson K.N. Simpson Impact of zidovudine-based triple combination therapy on an AIDS drug assistance program JAIDS 23 4 2000 302 313
30. L. Miller R. Hays Measuring adherence to antiretroviral medications in clinical trials HIV Clinical Trials 1 1 2001 36 46
31. Moore, R. D., Chaisson, R. E. Cost-utility analysis of prophylactic treatment with oral ganciclovir for cytomegalovirus retinitis. Journal of Acquired Immune Deficiency Syndrome (JAIDS) .
32. M. Portela K.N. Simpson H. Guess P.K. Sen K. Kilpatrick Markers and cofactors for progression in patients with HIV+ disease J. Mem. Inst. Oswaldo Cruz 92 4 1997 437 457
33. Red Book Drug Topics Medical Economics 1997 1997 Montvale NJ
34. G.K. Robbins D.J. Cotton Cost-effectiveness of ganciclovir for prevention of CMV retinitis Conf. Retroviruses Opportunistic Infect Jan. 22–26 1997 119 (4)
35. J.K. Rockstroh F. Bergmann W. Wiesel BID first-line ritonavir/indinavir 48 week results: German Multicenter Study 13th International AIDS Conference July 9–14; Durban SA 2000 Abstract TuPeB3206
36. D.N. Rose C.B. Schechter H.S. Sacks Influenza and pneumococcal vaccination for HIVinfected patients: a policy analysis Int Conf AIDS 7 1991 377
37. Schedule of Benefits: Physician services under the Health Insurance Act 2000 Ontario Ministry of Health, Publications Ontario Toronto, ON (1)
38. K. Simpson E.J. Hatziandreu F. Andersson A. Shakespeare I. Oleksey A.N.A. Tosteson Cost effectiveness of antiviral treatment with zalcitabine plus zidovudine for AIDS patients with CD4+ counts less than 300/ul in 5 European countries Pharmacoeconomics 6 1994 553 562
39. K.N. Simpson D. Marshall P. Thompson Measurement of Adherence to Clinical Protocol and Patient Outcomes: Examples from HIV+ Disease. Abstract 12th World AIDS Conference Geneva, Switzerland, July 2, 1998 1988
40. S. Staszewski J. Morales-Ramirez K.T. Tashima A. Rachlis D. Skiest J. Stanford R. Stryker P. Johnson D.F. Labriola D. Farina D.J. Manion N.M. Ruiz Efavirenz plus Zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team [see comments] New England Journal of Medicine 341 25 1999 186 573
41. J.V. Tu H.J. Biem A.S. Detsky Bronchoscopy versus empirical therapy in HIVinfected patients with presumptive Pneumocystis carinii pneumonia: A decision analysis Am. Rev. Respir. Dis. 148 2 1993 370 377
42. U.S. Health & Human Services: Panel on Clinical Practices for Treatment of HIV Infection Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents 2001 HIV/AIDS Treatment Information Service (February) http://www.hivatis.org
43. B. Varghese T.A. Peterman D.R. Holtgrave Cost-effectiveness of counseling and testing and partner notification: a decision analysis AIDS 13 13 1999 1745 1751